Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP777143.RAd52WhkOy1-cL-ap1R-2KulGZ442swun3ejQSLkSmynI130_assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP777143.RAd52WhkOy1-cL-ap1R-2KulGZ442swun3ejQSLkSmynI130_provenance.
• NP223589.RAT1Jw-Qo67AvAB2FBHBuLb2eLDReUnFU4MYsBz-MwXhY130_assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP223589.RAT1Jw-Qo67AvAB2FBHBuLb2eLDReUnFU4MYsBz-MwXhY130_provenance.
• assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP987766.RABFHyNOnu3rg91camPp6l70W9Fzm6iN7a8t0KQ6DvPdQ130_assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP987766.RABFHyNOnu3rg91camPp6l70W9Fzm6iN7a8t0KQ6DvPdQ130_provenance.
• NP444967.RABaHe9wZEhHk4dPS3iQpr9yz3jPFygYbJbMqaC8nnifU130_assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP444967.RABaHe9wZEhHk4dPS3iQpr9yz3jPFygYbJbMqaC8nnifU130_provenance.
• NP776497.RA4DY6KeQShZB7nsHCECStRMsFPDTwGSbNBYvI8XfhbCI130_assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP776497.RA4DY6KeQShZB7nsHCECStRMsFPDTwGSbNBYvI8XfhbCI130_provenance.
• NP444941.RA7HuSHT4PYYYXpjE5JA0XNnhaWQGqP70wE1NTIZJFx4U130_assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP444941.RA7HuSHT4PYYYXpjE5JA0XNnhaWQGqP70wE1NTIZJFx4U130_provenance.
• NP651448.RAbGyJB11GrnISDmKtEYKbeZfbszhc8JespQmlA6bMsIg130_assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP651448.RAbGyJB11GrnISDmKtEYKbeZfbszhc8JespQmlA6bMsIg130_provenance.
• NP651433.RA5TCGK4tf0NfxyIqyBese10RTtAzZNd9HwELvz3tAOYw130_assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP651433.RA5TCGK4tf0NfxyIqyBese10RTtAzZNd9HwELvz3tAOYw130_provenance.
• NP651450.RAyK-OLb8jSnDIk1_PqC6TstCF6MicSA77yQcIVP6iaHk130_assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP651450.RAyK-OLb8jSnDIk1_PqC6TstCF6MicSA77yQcIVP6iaHk130_provenance.
• assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP987768.RAZljRnWYgrXchKo5UvNCufa7JBJ_Ugycp53vAixktAek130_assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP987768.RAZljRnWYgrXchKo5UvNCufa7JBJ_Ugycp53vAixktAek130_provenance.
• NP697318.RA3Sb3GZkjvpC0O8Nf4mgMWsLsJ1hi3ihdt6A9T1Up3Vo130_assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP697318.RA3Sb3GZkjvpC0O8Nf4mgMWsLsJ1hi3ihdt6A9T1Up3Vo130_provenance.
• NP697319.RAwGrKdIQD3wDZvOQOVti4yJtN5qYVpMCy8lL2GeE7fQo130_assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP697319.RAwGrKdIQD3wDZvOQOVti4yJtN5qYVpMCy8lL2GeE7fQo130_provenance.
• NP697321.RA6ELOdyqlNNP_ImKBXBrwkKI_40r4WqaUaDD2bLyP1dQ130_assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP697321.RA6ELOdyqlNNP_ImKBXBrwkKI_40r4WqaUaDD2bLyP1dQ130_provenance.
• NP444965.RAPEsRjcjXoS-n_Eq1MmKV-8oMdlSk6rso2hhHnN80UzU130_assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP444965.RAPEsRjcjXoS-n_Eq1MmKV-8oMdlSk6rso2hhHnN80UzU130_provenance.
• NP697320.RAfe5UtmKcN5yz4fjqSqvNmotLwuV_lwhyQsbNdSR7Z34130_assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP697320.RAfe5UtmKcN5yz4fjqSqvNmotLwuV_lwhyQsbNdSR7Z34130_provenance.
• assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP987754.RAlxMVKa1IAFXynQ6-9IsL-Uu8zv0T_NgMLBTT-vQCDpU130_assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP987754.RAlxMVKa1IAFXynQ6-9IsL-Uu8zv0T_NgMLBTT-vQCDpU130_provenance.
• NP697317.RAgvSV0umciF28Oma9h0TnwHU_Hy8H7bHgnsi4rtz4Sqw130_assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP697317.RAgvSV0umciF28Oma9h0TnwHU_Hy8H7bHgnsi4rtz4Sqw130_provenance.